Linked Life Data

8031678

Source:http://linkedlifedata.com/resource/pubmed/id/8031678

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1994-8-17
pubmed:abstractText
The International Study Group's diagnostic criteria for Behçet's disease are gaining acceptance and may be further refined before the decade is over. Previously neglected clinical features of the disease, especially arterial aneurysms and phlebitis, are increasingly reported. Each poses a dilemma in the choice of treatment, which ranges from anticoagulant to immunosuppressant regimens, old and new. T-lymphocyte abnormalities, both in subpopulation and function, suggest ongoing presentation of an unknown antigen. Research on the role of HLA-B51, a split of B5, is moving centromeric to it in pursuit of a better disease marker. The choice of immunosuppressive therapy in severe disease such as uveitis and arteritis is between alkylating agents and agents that inhibit interleukin-2 production.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1040-8711
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
39-43
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Behçet's disease.
pubmed:affiliation
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905.
pubmed:publicationType
Journal Article, Review